Show simple item record

dc.contributor.authorHodgson, Darren R
dc.contributor.authorWellings, Robert
dc.contributor.authorOrr, Maria C M
dc.contributor.authorMcCormack, Rose
dc.contributor.authorMalone, Michael
dc.contributor.authorBoard, Ruth E
dc.contributor.authorCantarini, Mireille V
dc.date.accessioned2010-08-04T11:39:14Z
dc.date.available2010-08-04T11:39:14Z
dc.date.issued2010-02
dc.identifier.citationCirculating tumour-derived predictive biomarkers in oncology. 2010, 15 (3-4):98-101 Drug Discov Todayen
dc.identifier.issn1878-5832
dc.identifier.pmid20045486
dc.identifier.doi10.1016/j.drudis.2009.12.006
dc.identifier.urihttp://hdl.handle.net/10541/109044
dc.description.abstractMolecular characterization of tumour material will become increasingly important in selecting patients for clinical trials and offering appropriate treatment for patients in clinical practice. Recent advances in the field have indicated that the molecular characteristics of a tumour can be determined from circulating tumour cells and circulating tumour DNA; thus, a simple blood sample could provide these data in a simple, convenient and efficient manner. This article discusses progress towards guiding treatment decisions through measuring tumour-derived factors in the circulation.
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subjectCancer DNAen
dc.subjectLung Canceren
dc.subjectCanceren
dc.subjectCirculating Cancer Cellsen
dc.subjectBiological Tumour Markersen
dc.subject.meshColorectal Neoplasms
dc.subject.meshDNA, Neoplasm
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshNeoplasms
dc.subject.meshNeoplastic Cells, Circulating
dc.subject.meshPatient Selection
dc.subject.meshTumor Markers, Biological
dc.titleCirculating tumour-derived predictive biomarkers in oncology.en
dc.typeArticleen
dc.contributor.departmentOncology Therapy Area, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. darren.hodgson@astrazeneca.comen
dc.identifier.journalDrug Discovery Todayen
html.description.abstractMolecular characterization of tumour material will become increasingly important in selecting patients for clinical trials and offering appropriate treatment for patients in clinical practice. Recent advances in the field have indicated that the molecular characteristics of a tumour can be determined from circulating tumour cells and circulating tumour DNA; thus, a simple blood sample could provide these data in a simple, convenient and efficient manner. This article discusses progress towards guiding treatment decisions through measuring tumour-derived factors in the circulation.


Files in this item

This item appears in the following Collection(s)

Show simple item record